Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/anti-c-Met monoclonal antibody FPI-2053

A humanized bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), that can potentially be used as a ligand in radiotherapy. Upon administration, anti-EGFR/anti-c-Met monoclonal antibody FPI-2053 simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-EGFR x anti-c-Met monoclonal antibody FPI-2053
anti-EGFR/anti-c-Met bispecific antibody FPI-2053
anti-EGFR/c-Met antibody FPI-2053
Code name:FPI 2053
FPI-2053
FPI2053
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search